These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36254451)

  • 21. Commentary on Cousins et al. (2016): Accumulating evidence on risk of mortality on and off opioid substitution treatment.
    Hickman M; Macleod J; Degenhardt L
    Addiction; 2016 Jan; 111(1):83-4. PubMed ID: 26669528
    [No Abstract]   [Full Text] [Related]  

  • 22. Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence.
    Fishman MJ; Wu LT; Woody GE
    Am J Psychiatry; 2011 Jul; 168(7):675-9. PubMed ID: 21724673
    [No Abstract]   [Full Text] [Related]  

  • 23. Methadone and buprenorphine treatments in patients with schizophrenia.
    Dervaux A; Plancke L; Amariei A; Trouiller P; Tahon M; Martinetti MP; Naassila M; Cottencin O; Danel T
    Schizophr Res; 2019 Jul; 209():286-288. PubMed ID: 31101511
    [No Abstract]   [Full Text] [Related]  

  • 24. Low- and very low-dose buprenorphine induction: new(ish) uses for an old(ish) medication?
    Weimer MB; Fiellin DA
    Addiction; 2022 Jun; 117(6):1507-1509. PubMed ID: 35032081
    [No Abstract]   [Full Text] [Related]  

  • 25. Comorbid Health Conditions and Treatment Utilization among Individuals with Opioid Use Disorder Experiencing Homelessness.
    Ali MM; Sutherland H; Rosenoff E
    Subst Use Misuse; 2021; 56(4):571-574. PubMed ID: 33637031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expanding Buprenorphine Use in Primary Care: Changing the Culture.
    Leiser A; Robles M
    Perm J; 2022 Jun; 26(2):177-180. PubMed ID: 35933665
    [No Abstract]   [Full Text] [Related]  

  • 27. Novel forms of injectable buprenorphine and French model of opioid use disorder treatment.
    Lapeyre-Mestre M
    Therapie; 2020; 75(5):393-395. PubMed ID: 33039103
    [No Abstract]   [Full Text] [Related]  

  • 28. [Should high-dose buprenorphine be withdrawn from the French market?].
    Rolland B; Muyssen A; Danel T; Cottencin O
    Rev Epidemiol Sante Publique; 2013 Apr; 61(2):91-2. PubMed ID: 23489947
    [No Abstract]   [Full Text] [Related]  

  • 29. The case for a medication first approach to the treatment of opioid use disorder.
    Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
    Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
    [No Abstract]   [Full Text] [Related]  

  • 30. Potential for Precision Medicine in Methadone Treatment of Opioid Use Disorder.
    Saxon AJ
    J Addict Med; 2020; 14(5):362-363. PubMed ID: 32058338
    [No Abstract]   [Full Text] [Related]  

  • 31. Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021.
    Thakrar AP; Alexander GC; Saloner B
    JAMA Netw Open; 2021 Dec; 4(12):e2138807. PubMed ID: 34905010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prescribing psychologists: Forgotten providers in the battle against opioid use disorder.
    Hughes PM; Phillips DC; Fagan EB
    Addiction; 2023 Jul; 118(7):1398-1399. PubMed ID: 37039245
    [No Abstract]   [Full Text] [Related]  

  • 33. Opioid use disorder treatment for people experiencing homelessness: A scoping review.
    McLaughlin MF; Li R; Carrero ND; Bain PA; Chatterjee A
    Drug Alcohol Depend; 2021 Jul; 224():108717. PubMed ID: 33985863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medication-Based Treatment to Address Opioid Use Disorder.
    Leshner AI; Dzau VJ
    JAMA; 2019 Jun; 321(21):2071-2072. PubMed ID: 31046072
    [No Abstract]   [Full Text] [Related]  

  • 35. Controlling the Swing of the Opioid Pendulum.
    Comerci G; Katzman J; Duhigg D
    N Engl J Med; 2018 Feb; 378(8):691-693. PubMed ID: 29466151
    [No Abstract]   [Full Text] [Related]  

  • 36. "I'm on the Right Path": Exploring 1-Month Retention in a Homeless-Tailored Outpatient-Based Opioid Treatment Program.
    Fine DR; Critchley N; Hart K; Joyce A; Sporn N; Gaeta J; Wright J; Baggett TP; Kruse G
    Subst Use Addctn J; 2024 Apr; 45(2):268-277. PubMed ID: 38258838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical specialty of buprenorphine prescribers for pregnant women with opioid use disorder.
    Hollander MAG; Jarlenski MP; Donohue JM; Cole ES; Kelley D; Krans EE
    Am J Obstet Gynecol; 2019 May; 220(5):502-503. PubMed ID: 30703340
    [No Abstract]   [Full Text] [Related]  

  • 38. Availability of Extended-Release Buprenorphine to Treat Opioid Use Disorders Among Medicaid-Covered Patients.
    Shover CL
    Psychiatr Serv; 2021 Feb; 72(2):225-226. PubMed ID: 32907476
    [No Abstract]   [Full Text] [Related]  

  • 39. Medicines for Patients After an Opioid Overdose.
    Ann Intern Med; 2018 Aug; 169(3):. PubMed ID: 29913484
    [No Abstract]   [Full Text] [Related]  

  • 40. Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.
    Balhara YP
    J Opioid Manag; 2013; 9(4):237. PubMed ID: 24380101
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.